Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04760964 |
| Other study ID # |
AC19037 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 27, 2021 |
| Est. completion date |
December 31, 2025 |
Study information
| Verified date |
June 2024 |
| Source |
University of Edinburgh |
| Contact |
Gwo-Tzer Ho |
| Phone |
01312426653 |
| Email |
G.Ho[@]ed.ac.uk |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The MUSIC study is a multi-centre, longitudinal study set in the real world IBD clinical
setting to investigate and develop a new biomarker approach that aims to inform both patients
and clinicians of the current state of the affected gut lining (how inflamed or whether the
bowel wall has completely healed).
This new biomarker approach will study a panel of molecular signs in IBD patients' blood,
stools and biopsies that will be correlated to the current gold standard of direct gut visual
examination using ileo-colonoscopy and flexible sigmoidoscopy tests (a fibre-optic
examination of the lower small bowel and large bowel). Here, the state and appearances of IBD
patients' gut lining will be assessed over one year in response to treatment given to them by
their NHS IBD consultant.
This approach will focus on the role of damage associated molecular patterns (DAMPs), also
known as 'danger signals'. DAMPs are found in our own cells and are released during tissue
stress or injury. Like signals from bacteria, they can trigger inflammation. In the MUSIC
study, blood, stool, saliva and gut samples obtained from participants during active IBD and
in clinical remission will be used in order to understand how DAMPs contribute to the
development of gut inflammation.
Description:
The hypothesis is that mitochondrial DAMPs are good mechanistic biomarkers for mucosal
inflammation and healing in IBD.
Complete mucosal healing (total resolution and absence of ulcerations in the gut) is the most
sought-after treatment target with the best long-term implication in prognosis.
Up to now IBD clinicians rely on (1) clinical symptoms (how patients feel, their bowel habit,
presence of blood in stools), (2) clinical tests such as stool calprotectin (FC) and blood
C-reactive protein (CRP) to inform both themselves and the patients, how well the drug
treatment is working and importantly, whether the ulcers and inflammation seen in the gut
lining have healed or not.
Current evidence shows that these approaches are not fully informative. For example, 30% of
patients with significant subjective improvement in their symptoms following treatment of
active CD have evidence of active inflammation in their gut lining when further assessed with
an ileo-colonoscopy. Blood and stool tests to predict mucosal healing are only useful in
around 60-70% and very limited, in guiding the doctors in how severely inflamed the bowel
wall is during active IBD.
Direct visualisation using ileo-colonoscopy or flexible sigmoidoscopy is the most accurate
approach to assess disease activity and mucosal healing in response to medical treatment. By
knowing precisely, how the gut wall inflammation is responding to treatment, the clinician
can accurately manage the IBD patient (by either changing the dose and type of treatment, and
whether to carry on with expensive, strong medications with potentially serious side
effects). However, in the real world, follow-up endoscopic tests are difficult to carry out
as they are expensive and we lack the capacity to undertake these examinations within NHS.
Project Goals
The main goal for the MUSIC study is to investigate the role of mitochondrial DAMPs in the
clinic as an indicator of gut inflammation and subsequent mucosal healing in response to
medical treatment in IBD.
Secondly, further scientific studies will be carried out using blood, stool, saliva and gut
biopsy samples to investigate how mitochondrial DAMPs (and all known biomarkers and
biological data such as genetics) contribute to the abnormal development of gut inflammation
in IBD.
Primary research questions:
- Do mitochondrial DAMPs predict the activity and severity of IBD-inflammation?
- Does normalisation of mitochondrial DAMPs reflect complete endoscopic mucosal healing in
IBD?
- How do mitochondrial DAMPs compare to current biomarkers (FC, CRP) and clinical symptoms
(HBI/Mayo Score) in assessing IBD inflammation and mucosal healing?
- Can a simple decision-making model be developed to predict mucosal healing based on
mitochondrial DAMPs, together with relevant biological data such as genetics, blood
transcriptomics, microbiome; and current clinical biomarkers such as calprotectin,
faecal haemoglobin and blood CRP?
Secondary research questions:
- How are mitochondrial DAMPs released from cells in the IBD gut?
- What types of cells are important in mitochondrial DAMP release? There are many forms of
inflammatory cells in affected IBD gut (e.g. macrophage, epithelial, neutrophils). It is
possible that different cell types may contain more inflammatory DAMPs.
- Which type of mitochondrial DAMPs are important in causing inflammation? Can
mitochondrial DAMPs pinpoint a specific underlying genetic susceptibility (e.g.
autophagy) or inflammatory mechanism in IBD?
Rationale
The focus is to investigate mitochondrial DAMPs' utility in two clinically relevant
scenarios: (a) How severe or active is the disease? (b) How well are we treating IBD? - with
endoscopic endpoints of mucosal inflammation and healing respectively. The Simple Endoscopic
Score for Crohn's Disease (SES-CD) and Endoscopic Mayo Score (eMS) will be used for CD and UC
respectively. Both have been validated and used widely in research and in clinical trials. By
using these objective endoscopic endpoints, mtDAMPs (and in combination with current
biomarkers FC and CRP) can be tested across a range of mucosal inflammation (full healing to
severe).
In addition to this, it will be investigated if mitochondrial DAMPs can identify a
subclinical pathogenic mechanism (e.g. [a] defective autophagy to clear damaged mitochondria;
[b] de-regulated innate immune response to mitochondrial DAMPs.) These data will pave the way
for future use of mitochondrial DAMP biomarkers as part of a stratified approach for new
treatments targeted at mitochondrial DAMPs and their downstream inflammatory mechanisms in
IBD.
Study Population
Presently within usual NHS care, all patients with active IBD, especially those to be
initiated on biologic or immunomodulator treatment, are followed up where they will have
documentation of disease activity (Harvey Bradshaw Index [HBI] or UC Mayo Score [MS], stool
calprotectin, C-reactive protein, albumin and blood count) to assess their well-being and
response to medical treatment.
With MUSIC, patients will be followed up prospectively (aligning the usual NHS clinical care
above) and will receive additional endoscopic follow-up to assess mucosal healing in response
to medical treatment. Thus, the MUSIC study will incorporate a prospective endoscopic
evaluation of mucosal inflammation and mucosal healing into IBD clinics.
The recruitment and subsequent clinical data and sample collection will take place at 0, 3,
6, 9 and 12 months.
